[1]
Peters, A. 2022. Safety and tolerability of Bruton’s tyrosine kinase inhibitors in the treatment of Waldenström macroglobulinemia. Canadian Hematology Today. 1, S06 (Jun. 2022). DOI:https://doi.org/10.58931/cht.2022.1S0628.